{"abdominal pain": 2.03, "abdominal pain upper": 2.32, "aspartate aminotransferase increased": 2.11, "blast crisis in myelogenous leukaemia": 112.45, "chronic graft versus host disease": 38.72, "chronic myeloid leukaemia": 79.52, "chronic myeloid leukaemia recurrent": 111.15, "cytogenetic analysis abnormal": 374.34, "cytopenia": 23.78, "dermatitis allergic": 3.62, "disease progression": 4.04, "drug ineffective": 2.19, "drug interaction": 3.85, "drug intolerance": 17.76, "drug resistance": 47.78, "dyspepsia": 2.49, "eyelid oedema": 11.71, "face oedema": 7.65, "febrile neutropenia": 2.32, "fluid retention": 6.34, "gamma-glutamyltransferase increased": 2.17, "gastrointestinal stromal tumour": 208.19, "gene mutation": 36.99, "generalised oedema": 14.4, "haematotoxicity": 16.79, "hepatotoxicity": 5.81, "malignant neoplasm progression": 9.08, "metastases to liver": 16.25, "muscle spasms": 2.83, "myelosuppression": 2.27, "neurotoxicity": 5.13, "neutropenia": 2.28, "oedema": 5.61, "oedema peripheral": 3.41, "pancytopenia": 5.63, "pericardial effusion": 3.0, "periorbital oedema": 28.41, "philadelphia chromosome positive": 159.41, "pleural effusion": 3.18, "product substitution issue": 42.42, "product use in unapproved indication": 2.05, "second primary malignancy": 16.12, "skin exfoliation": 2.42, "splenomegaly": 6.78, "therapeutic response decreased": 6.95, "therapy non-responder": 10.28, "thrombocytopenia": 2.76, "treatment failure": 10.8, "type 2 diabetes mellitus": 5.92, "white blood cell count increased": 3.91}